TEL:
 +44
 191
 419
 4488

 FAX:
 +44
 191
 419
 5693

 Email:
 sales@rocketmedical.com

 www.rocketmedical.com



FSN Ref: INTCOMP131-FSN

FSCA Ref: INTCOMPI31-FSCA

Date: DD MM YYYY

It is important that your organisation takes the actions detailed in the FSN and confirms that you have received the FSN.

Your organisation's reply is the evidence we need to monitor the progress of the corrective actions.

Urgent Field Safety Notice Rocket KCH™ Fetal Bladder Drain R57405 Device Destruction

For Attention of: Persons responsible for medical device vigilance / risk management Clinicians in the fetal medicine department Distributors of the device

Contact details of local representative: For further information, please contact: Regulatoryaffairs@rocketmedical.com **ROCKET MEDICAL PLC** SEDLING ROAD WASHINGTON TYNE & WEAR NE38 9BZ ENGLAND

TEL: +44 191 419 4488 FAX: +44 191 419 5693 Email: sales@rocketmedical.com www.rocketmedical.com



FSN Ref: INTCOMP131-FSN

FSCA Ref: INTCOMP131-FSCA

Urgent Field Safety Notice Rocket KCH[™] Fetal Bladder Drain R57405 **Device Destruction Material Non-Conformance**

	I. Information on Affected Devices
Ι	I. Device Type(s)
	Rocket KCH [™] Fetal Bladder Drain Procedure kit is a sterile, single-use device intended to create a fetal-amniotic shunt to treat fetal lower urinary tract outflow obstruction by allowing the urine to flow from the baby's bladder into the amniotic sac, bypassing the urinary tract. The device contains a double pigtail stent with an outer tube diameter of 2.1mm and inner tube diameter of 1.5mm.
	Fetal coil
1	2. Commercial name(s)
•	Rocket KCH™ Fetal Bladder Drain
	Rocket KCH™ Fetal Bladder Catheter
Ι	3. Unique Device Identifier(s) (UDI-DI)
	R57405
I	4. Primary clinical purpose of device(s)
	The device is indicated for use in fetal bladder decompression following the diagnosis of fetal
	post-vesicular obstructive uropathy in fetuses of 18-32 weeks gestation.
	5. Device Model/Catalogue/part number(s)
	R57405
I	6. Software version
	N/A – This device is not software and nor does it incorporate software.
Ι	7. Affected serial or lot number range
	00000000468148, 00000000469156, 00000000475024, 00000000475494,
	00000000477211, 00000000479414, 00000000479735, 00000000480062,
L	00000000480196, 00000000482145, 00000000484317, 00000000485443.
I	8. Associated devices
	N/A – There are no other devices associated with this FSN.

Reason for Field Safety Corrective Action (FSCA) 2.

- 2 I. Description of the product problem An error has been made in which material of an inferior quality was provided and used in the manufacture of the device. It is understood that the difference in the quality of the materials is limited to Quality Controls around their manufacture, the material used in manufacture having lower controls. 2
 - 2. Hazard giving rise to the FSCA

 TEL:
 +44 191 419 4488

 FAX:
 +44 191 419 5693

 Email:
 sales@rocketmedical.com

 www.rocketmedical.com



FSN Ref: INTCOMP131-FSN

FSCA Ref: INTCOMP131-FSCA

	Sales of the device have been suspended whilst we investigate the impact of the use of this		
	material.		
2	3. Probability of problem arising		
	Further evaluation is required. To date, no incidents have been reported as a consequence of this		
	issue.		
2	4. Predicted risk to patient/users		
	It is not possible to estimate the risk to patients until further evaluation of this issue has been		
	completed.		
2	5. Further information to help characterise the problem		
	N/A – No further information.		
2	6. Background on Issue		
	No incidents have been reported as a consequence of this issue.		
	An error has been made in which material of an inferior quality was used in the manufacture of		
	the device. It is understood that the difference in the quality of the materials is limited to Quality		
	Controls around their manufacture, the material used in manufacture having lower controls. We		
	do not know the impact of the use of the incorrect material; a review is underway. In the		
	meantime, we have suspended product sales and we are issuing this FSN to address product in		
	the field.		
2	7. Other information relevant to FSCA		
	Sales of the device continue to be suspended. This field safety corrective action is being		
	implemented to destroy any unused product on the market. At this time, no action is considered		
	justified for patients with an implanted device.		

	3. Type of Action to mitigate the risk				
3	١.	Action To Be T	aken by the User		
		□ Identify Device	□ Quarantine Device	□ Return Device	⊠ Destroy Device
		□ On-site device modification/inspection			
		□ Follow patient ma	anagement recommendations		
		□ Take note of ame	endment/reinforcement of Insti	ructions For Use (IFU)	
		□ Other	□ None		
		Without delay, identify any KCH™ Fetal Bladder Drains / KCH Fetal Bladder Catheters (REF R57405) in stock. Destroy all devices not yet implanted. Rocket Medical will replace or reimburse all destroyed devices.			
		Please confirm that you have received this communication and undertaken the required actions by completing and returning the attached "Customer Response" form.			
		has been transferr	aff members are informed o red/supplied to another facili ately by providing a copy of	ty or organisation, pl	



FSN Ref: INTCOMP131-FSN

FSCA Ref: INTCOMP131-FSCA

	At this time and based on the information available, no action is recommended for devices				
		already implanted. The device is critical for the pre-natal survival of the fetus already			
		implanted with this device. Any potential remedial action, such as replacing the device with an alternative or expediting delivery, is considered to carry greater risk than leaving			
			lelivery, is considered to carry grea	ater risk than leaving	
		implanted devices in situ.			
		All queries regarding this ESN	N should be directed to Rocket Me	dical PLC through the email	
		address Regulatoryaffairs@ro			
		3 , 3			
3	2.	By when should the	Immediately and without delay.		
		action be completed?			
3	3.	Particular considerations	for: implantable device		
		le felleur un of notionte or	· ····································	a sulta va sa manan da d?	
			review of patients' previous r r testing has been undertaken to he		
			evice implanted, Rocket Medical wi		
~	regarding appropriate follow-up of those patients.				
3	4.	Is Customer Reply Requi	red?	Yes	
3		Is Customer Reply Requir ease complete and return appl		Yes	
3	(Ple	Is Customer Reply Requine ease complete and return appl Action Being Taken by	icable form(s).)	Yes	
	(Ple	ease complete and return appl	icable form(s).)	Yes	
	(Ple	ease complete and return appl Action Being Taken by	icable form(s).)		
	(Ple	ease complete and return appl Action Being Taken by ⊠ Product Removal	icable form(s).) the Manufacturer		
	(Ple	ease complete and return appl Action Being Taken by Image: Specific Structure	icable form(s).) the Manufacturer On-site device modification/inspectior		
	(Ple	ease complete and return appl Action Being Taken by ⊠ Product Removal □ Software upgrade □ Other	icable form(s).) the Manufacturer On-site device modification/inspectior IFU or labelling change None	1	
	(Ple	ease complete and return appl Action Being Taken by ☑ Product Removal □ Software upgrade □ Other □ Further actions, including addition	icable form(s).) the Manufacturer On-site device modification/inspectior IFU or labelling change	1	
3	(Ple 5.	ease complete and return appl Action Being Taken by □ Product Removal □ □ Software upgrade □ □ Other □ Further actions, including addition market.	icable form(s).) the Manufacturer On-site device modification/inspection IFU or labelling change None onal testing, are being undertaken to a	1	
	(Ple 5.	Action Being Taken by Product Removal Software upgrade Other Further actions, including addition market. By when should the	icable form(s).) the Manufacturer On-site device modification/inspectior IFU or labelling change None	1	
3	(Ple 5.	Action Being Taken by Action Being Taken by Product Removal Software upgrade Other Further actions, including additionarket. By when should the action be completed?	icable form(s).) the Manufacturer On-site device modification/inspection IFU or labelling change None onal testing, are being undertaken to a As soon as possible.	llow return of the device to the	
3	(Ple 5.	ease complete and return appl Action Being Taken by ☑ Product Removal □ Software upgrade □ Other □ Further actions, including addition market. By when should the action be completed? Is the FSN required to be	icable form(s).) the Manufacturer On-site device modification/inspection IFU or labelling change None onal testing, are being undertaken to a As soon as possible.	1	
3 3	(Pla 5. 6. 7.	ease complete and return appl Action Being Taken by □ □ Product Removal □ Software upgrade □ Other □ Other □ Further actions, including addition market. By when should the action be completed? Is the FSN required to be patient /lay user?	icable form(s).) the Manufacturer On-site device modification/inspection IFU or labelling change None onal testing, are being undertaken to a As soon as possible. e communicated to the	llow return of the device to the	
3	(Pla 5. 6. 7.	Action Being Taken by Action Being Taken by □ Product Removal □ □ Software upgrade □ □ Other □ Further actions, including addition market. By when should the action be completed? Is the FSN required to be patient /lay user? If yes, has manufacturer patient of the statement of the st	icable form(s).) the Manufacturer On-site device modification/inspection IFU or labelling change None onal testing, are being undertaken to a As soon as possible. communicated to the provided additional informatio	Ilow return of the device to the No n suitable for the	
3 3	(Pla 5. 6. 7.	Action Being Taken by Action Being Taken by □ Product Removal □ □ Software upgrade □ □ Other □ Further actions, including addition market. By when should the action be completed? Is the FSN required to be patient /lay user? If yes, has manufacturer patient of the statement of the st	icable form(s).) the Manufacturer On-site device modification/inspection IFU or labelling change None onal testing, are being undertaken to a As soon as possible. e communicated to the	Ilow return of the device to the No n suitable for the	

		4. General Information	
4	١.	FSN Type	New
4	2.	For updated FSN, reference number and date of previous FSN	N/A – This is a new FSN.
4	3.	3. For Updated FSN, key new information as follows:	
		N/A – This is a new FSN.	

 TEL:
 +44
 191
 419
 4488

 FAX:
 +44
 191
 419
 5693

 Email:
 sales@rocketmedical.com

 www.rocketmedical.com



FSN Ref: INTCOMP131-FSN

FSCA Ref: INTCOMP131-FSCA

4	4. Further advice or information	Yes.
	already expected in follow-up	103.
	FSN?	
		is the further advice even ated to relate to
	5. If follow-up FSN expected, what	is the further advice expected to relate to:
4	The follow-up FSN is expected to pro	ovide information regarding appropriate follow-up of
patients previously implanted with this device.		s device.
	6. Anticipated timescale for	May 2021
4	follow-up FSN	
4	7. Manufacturer information	
	(For contact details of local representative ref	fer to page 1 of this FSN)
	a. Company Name	Rocket Medical PLC
	b. Address	Sedling Road, Washington, Tyne & Wear, NE38
		9BZ, England
	c. Website address	www.rocketmedical.com
4	8. The Competent (Regulatory) A	uthority of your country has been informed
	about this communication to cus	stomers.
4	9. List of attachments/appendices:	- Customer Response Form
4.	10. Name/Signature	
		Rocket Medical PLC

Transmission of this Field Safety Notice This notice needs to be passed on to all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate) Please transfer this notice to other organisations on which this action has an impact. (As appropriate) Please maintain awareness of this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.

 TEL:
 +44 191 419 4488

 FAX:
 +44 191 419 5693

 Email:
 sales@rocketmedical.com

 www.rocketmedical.com



FSN Ref: INTCOMP131-FSN

FSCA Ref: INTCOMP131-FSCA

Customer Response Form

I. Field Safety Notice (FSN) information	
FSN Reference number	INTCOMP131-FSN
FSN Date	DD MM YYYY
Product/ Device name	Rocket KCH™ Fetal Bladder Drain
Product Code(s)	R57405
Batch/Serial Number (s)	00000000468148, 00000000469156,
	00000000475024, 000000000475494,
	00000000477211, 00000000479414,
	00000000479735, 00000000480062,
	00000000480196, 00000000482145,
	00000000484317, 000000000485443.

2. Customer Details	
Healthcare Organisation Name	
Organisation Address	
Department/Unit	
Contact Name	
Title or Function	
Telephone number	
Email	

3. C	Customer action undertaken on behalf of Healthcare Organisation		
	I confirm receipt of the	Comment	
	Field Safety Notice and		
	that I read and		
	understood its content.		
	I have/will perform all	Comment	
	actions requested by the FSN.		
	The information and required actions have been brought to the	Comment	
	attention of all relevant		
	I have destroyed the	Number of devices:	
	following number of		
	devices:		
	The Batch/Serial Number	Serial / LOT number (required for replacement / reimbursement):	
	(SN or LOT) for devices		
	destroyed are:		
	I do not have any affected	Comment	
	devices.		
	Name		
Signat	cure		
Date			

 TEL:
 +44 191 419 4488

 FAX:
 +44 191 419 5693

 Email:
 sales@rocketmedical.com

 www.rocketmedical.com



FSN Ref: INTCOMP131-FSN

FSCA Ref: INTCOMP131-FSCA

4. Return acknowledgement to:	
Email	regulatoryaffairs@rocketmedical.com
Subject of e-mail	"INTCOMP131-FSN Response"
Deadline for returning the Customer Response	Immediately / As soon as possible.
form	